Investor Presentaiton

BION-300: Summary and next steps Carrier platform enabling intracellular delivery of biologics targeting "undruggable" proteins In vitro, proof-of- concept studies have demonstrated: antibody internalization endosomal escape cytoplasm dispersibility functional target binding Preliminary in vivo studies have demonstrated efficient pharmacokinetics and biodistribution BIOND BIOLOGICS Biond Biologics Corporate Presentation | May 2021 | Non-confidential 39

View entire presentation